

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
17 January 2008 (17.01.2008)

PCT

(10) International Publication Number
WO 2008/007074 A2

(51) International Patent Classification:
C07D 279/18 (2006.01)

(21) International Application Number:
PCT/GB2007/002570

(22) International Filing Date: 10 July 2007 (10.07.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/819,627 11 July 2006 (11.07.2006) US

(71) Applicant (for all designated States except US): **WISTA LABORATORIES LTD.** [SG/SG]; 51 Ayer Rajah Crescent, #07-01/02 Singapore, Singapore 139948 (SG).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **WISCHIK, Claude, Michel** [FR/GB]; WisTa Laboratories Ltd., Institute of Medical Sciences, Forresterhill, Aberdeen, Aberdeenshire AB24 1RQ (GB). **STOREY, John, Mervyn, David** [GB/GB]; WisTa Laboratories Ltd., Department of Chemistry, Meston Walk, Old Aberdeen, Aberdeenshire AB24 3UE (GB). **MARSHALL, Colin** [GB/GB]; WisTa Laboratories Ltd., Department of Chemistry, Meston Walk, Old Aberdeen, Aberdeen AB24 3UE (GB). **SINCLAIR,**

James, Peter [GB/GB]; WisTa Laboratories Ltd., Department of Chemistry, Meston Walk, Old Aberdeen, Aberdeenshire AB24 3UE (GB). **BADDELEY, Thomas, Craven** [GB/GB]; WisTa Laboratories Ltd., Department of Chemistry, Meston Walk, Old Aberdeen, Aberdeenshire AB24 3UE (GB).


(74) Agents: **WYTENBURG, Wilhelmus** et al.; Mewburn Ellis LLP, York House, 23 Kingsway, London, Greater London WC2B 6HP (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL,

[Continued on next page]

(54) Title: METHODS OF SYNTHESIS AND/OR PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS



(57) Abstract: This invention pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesis and/or purification of certain 3,7 diamino-phenothiazin-5-ium compounds (referred to herein as "diaminophenothiazinium compounds") including Methylthioninium Chloride (MTC) (also known as Methylene Blue). The present invention also pertains to the resulting (high purity) compounds, compositions comprising them (e.g., tablets, capsules), and their use in methods of inactivating pathogens, and methods of medical treatment, prophylaxis, and diagnosis, etc., for example, a tauopathy; a disease of tau protein aggregation; Alzheimer's disease (AD); Pick's disease; Progressive Supranuclear Palsy (PSP); fronto temporal dementia (FTD); parkinsonism linked to chromosome 17 (FTDP-17); disinhibition-dementia-parkinsonism-amyotrophy complex (DDPAC); pallido-ponto-nigral degeneration (PPND); Guam-ALS syndrome; pallido-nigro-lusian degeneration (PNLD); cortico-basal degeneration (CBD); mild cognitive impairment (MCI); skin cancer; melanoma; methemoglobinemia; a viral infection; a bacterial infection; a protozoal infection; a parasitic infection; malaria; visceral leishmaniasis; African sleeping sickness; toxoplasmosis; giardiasis; Chagas' disease; Hepatitis C virus (HCV) infection; human immunodeficiency virus (HIV) infection; West Nile virus (WNV) infection; a synucleinopathy; Parkinson's disease (PD); dementia with Lewy bodies (DLB); multiple system atrophy (MSA); drug-induced parkinsonism; and pure autonomic failure (PAF).



WO 2008/007074 A2



PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Declaration under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *without international search report and to be republished upon receipt of that report*